Safety and Efficacy of Restylane Vital for Skin Rejuvenation of Dorsal Hands
Launched by GALDERMA R&D · Sep 7, 2015
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed Informed Consent
- • Chinese origin
- • Subject willing and able to comply with the requirements of the study and agrees to adhere to the visit schedule and to be compliant to the study instructions
- Exclusion Criteria:
- • Any previous non-permanent implant/filler in the hands
- • Any mesotherapy or resurfacing procedure in the hands within 6 months prior to baseline
- • Any previous hand surgery
- • Any fibrosis or scarring or deformities on the hands
- • Advanced photoaged/photodamaged skin
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Beijing, , China
Beijing, , China
Patients applied
Trial Officials
Q-Med AB
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials